Skip to content

Study · Non-randomized trial · n = 20 · 1998

2 results

Differential behavioral effects of gonadal steroids in women with and in those without premenstrual syndrome.

Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR

The New England journal of medicine1 Jan 1998Cited by 496 (Europe PMC)

PMID9435325 (opens in a new tab)DOI10.1056/nejm199801223380401 (opens in a new tab)PepBankPUB-09435325
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In women with premenstrual syndrome, leuprolide significantly reduced symptoms compared with placebo.

    In plain wordsIn women with premenstrual syndrome, leuprolide reduced symptoms compared with placebo.

    Peptide
    Leuprolide
    Outcome
    DecreasePremenstrual symptoms versus placebo
    Study

    n = 20

    Comparator
    Placebo
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The 10 women with premenstrual syndrome who were given leuprolide had a significant decrease in symptoms as compared with base-line values and with values for the 10 women who were given placebo.
    2 context sentences
    Summary · context
    We first studied the effect of ovarian suppression with leuprolide, an agonist analogue of gonadotropin-releasing hormone, or placebo on symptoms in 20 women with the premenstrual syndrome.
    Summary · context
    Outcomes were assessed on the basis of daily self-reports by the patients and biweekly rater-administered symptom-rating scales.
  2. 02HumanNon-randomized trialEfficacy outcome

    In women with premenstrual syndrome, leuprolide significantly reduced symptoms compared with baseline.

    In plain wordsIn women with premenstrual syndrome, symptoms decreased from baseline with leuprolide.

    Peptide
    Leuprolide
    Outcome
    DecreasePremenstrual symptoms versus baseline
    Study

    n = 10

    Comparator
    Baseline
    Outcome group
    Anxiety and mood · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The 10 women with premenstrual syndrome who were given leuprolide had a significant decrease in symptoms as compared with base-line values and with values for the 10 women who were given placebo.
    2 context sentences
    Summary · context
    We first studied the effect of ovarian suppression with leuprolide, an agonist analogue of gonadotropin-releasing hormone, or placebo on symptoms in 20 women with the premenstrual syndrome.
    Summary · context
    Outcomes were assessed on the basis of daily self-reports by the patients and biweekly rater-administered symptom-rating scales.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials4

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

4 trials · 4 completed · 4 with posted results · source ClinicalTrials.gov (opens in a new tab)

CompletedPhase 2Results postedNCT04225221

Neurobiology of Bulimia Nervosa

University of North Carolina, Chapel Hilln = 1024 Feb 2020 to 4 Apr 2022

Bulimia Nervosa

Trial pageClinicalTrials.govUpdated 26 Jul 2022
CompletedPhase 2Results postedNCT04051320

Characterizing the Neural Substrates of Irritability in Women: an Experimental Neuroendocrine Model

University of North Carolina, Chapel Hilln = 232 Jan 2020 to 19 Jul 2022

Perinatal Depression · Post Partum Depression · Depression, Postpartum · Depression

Trial pageClinicalTrials.govUpdated 25 Aug 2023
CompletedPhase 1/2Results postedNCT00001322

The Effects of Reproductive Hormones on Mood and Behavior

National Institute of Mental Health (NIMH)n = 1009 Jun 1994 to 3 Mar 2020

Healthy Volunteers

Trial pageClinicalTrials.govUpdated 22 Mar 2022
CompletedPhase 1Results postedNCT00001259

A Treatment Study for Premenstrual Syndrome (PMS)

National Institute of Mental Health (NIMH)n = 6011 Aug 1992 to 6 Feb 2020

Premenstrual Syndrome · Menstruation Disturbances

Trial pageClinicalTrials.govUpdated 2 Mar 2023

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:37 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.